You are right, a poor prognosis was a pre-requisite for the trial. If the cells are effective then that should aid in separation between them and placebo, and as the company has said a number of times. The sicker people are, the better they tend to respond to the Ryoncil treatment.
Interesting that the two trials have differing end points, and the Athersys trial makes virtually no mention of Biomarkers at all. On the other hand maybe where good efficacy is observed vs control the biomarkers are irrelevant.
Competition - Citius Novellus License Deal, page-6
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.040(2.65%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.48 | $1.45 | $2.567M | 1.757M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1400 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 20509 | 7 |
View Market Depth
| Last trade - 11.10am 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |